Seeking Alpha Portfolio App for iPad
Dividends & Income
I work for Cytori Therapeutics (NASDAQ: CYTX) as the Director for Investor Relations. Feel free to contact me by phone at 858.875.5258 or email at email@example.com
Stocks - long
Cytori (NASDAQ: CYTX) is developing cell therapies for cardiovascular disease and for the repair of soft tissue injuries and burns. Cytori’s Cell Therapy is comprised of an individual’s own adipose derived stem and regenerative cells uniquely optimized and formulated for specific therapeutic applications. In
the U.S. we are conducting a clinical trial of the Cytori cell therapy in patients who suffer from a severe form of refractory (untreatable) heart failure due to chronic myocardial ischemia. Additionally, we are developing a treatment of thermal burns combined with radiation injury as part of a contract valued at up to $106 million from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA). To encourage further research into the potential of Cytori’s cell therapy, we offer our cell therapy platform, including a patented and proprietary point-of-care device, consumables, and specialized reagents, to academic researchers and partners around the world. In parallel, we are seeking to expand market access of our products in Europe, Asia and other emerging markets for a variety of conditions, including heart attacks, other vascular applications, and soft tissue applications.
Currently, there are no book details for CytoriIR.
The Opinion Leaders
Xignite quote data
© 2013 Seeking Alpha